Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

3 Diabetes Stocks That are Better Investments Than Senseonics

3 Diabetes Stocks That are Better Investments Than Senseonics

Despite the ongoing global public health crisis, fundamentally-sound companies focused on diabetic treatments are seemingly unfazed. So, given Senseonics' (SENS) relative overvaluation and bleak growth prospects, we think it could be wise to bet on diabetes stocks Novo Nordisk (NVO), Eli Lilly (LLY), and Abbott Laboratories (ABT). Let’s discuss.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

ImmunoGen Inc (NASDAQ: IMGN) has

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

4 Top Dividend Growth Stocks to Add to Your Watchlist

Dividend investing is an effective way of generating income with limited concern about market volatility. So, investors looking to assure a consistent flow of income, along with capital appreciation, could consider adding quality dividend stocks Microsoft (MSFT), Eli Lilly (LLY), Zoetis (ZTS), and The TJX (TJX) to their watchlists. These…

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US

Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US

Eli Lilly And Co (NYSE: LLY)

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 12.31% on an annualized basis.

Get all your
news in one place.

100's of premium titles.
One news app.

Expert Ratings For Eli Lilly

Over the past 3 months, 7 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases

Abbisko Therapeutics has entered into a worldwide collaboration and exclusive licensing agreement with Eli Lilly And Co (NYSE: LLY) for novel molecules against an

1 … 11 12 13 14

Organisations

Johnson & Johnson (

Abbott Laboratories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

401,731 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play